Advertisement

Therapie von oxidativem Streß

  • M. Rösler
  • W. Retz

Zusammenfassung

Die Annahme, daβ oxidativer Streβ im Rahmen der Ätiopathogenese der Alzheimer Krankheit (DAT) eine wichtige Rolle spielen könnte, wird heute als vergleichsweise gut abgesicherte Hypothese angesehen. Man knüpft dabei an überlegungen an, die im Zusammenhang mit natürlichen Alterungsvorgängen und anderen neurodegenerativen Krankheiten schon intensiv erörtert worden sind. Besonders bei der Parkinsonschen Krankheit oder der amyotrophen Lateralsklerose wird dem Modell des neuronalen Zellunterganges durch oxidativen Streβ erhebliche Bedeutung zugesprochen (Hal-Liwell 1992, Jenner 1994, Frölich und Riederer 1995).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Agnoli A, Martucci N, Fabbrini G, Buckley A, Fioravanti M (1990) Monoamine oxidase and dementia: treatment with an inhibitor of MAOB activity. Dementia 1: 109–114Google Scholar
  2. Agnoli A, Fabbrini G, Fioravanti M, Martucci N (1992) CBF and cognitive evaluation of Alzheimer type patients before and after IMAOB treatment: a pilot study. Eur Neuropharmacol 2: 31–35CrossRefGoogle Scholar
  3. Bell J, Beglan C, London E (1996) Interaction of ascorbic acid with the neurotoxic effects of NMDA and sodium nitroprusside. Life Sci 58: 367–371PubMedCrossRefGoogle Scholar
  4. Bergamasco B, Scarzella L, La Commare P (1994) Idebenone, a new drug in the treatment of cognitive impairment in patients with senile dementia of the Alzheimer type. Funct Neurol 9: 161–168PubMedGoogle Scholar
  5. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1 bete and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202: 17–20PubMedCrossRefGoogle Scholar
  6. Bruno V, Battaglia G, Copani A, Sortino MA, Canonico PL, Nicoletti F (1994) Protective action of idebenone against excitotoxic degeneration in cultured cortical neurons. Neurosci Lett 178: 193–196PubMedCrossRefGoogle Scholar
  7. Burke W, Ranno A, Roccaforte W, Wengel S, Bayer B, Willcockson N (1993a) L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results. J Am Geriatr Soc 41: 367–370PubMedGoogle Scholar
  8. Burke W, Roccaforte W, Wengel S, Bayer B, Ranno A, Willcockson N (1993b) L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 41: 1219–1225PubMedGoogle Scholar
  9. Burns A, Marsh A, Bender D (1989) A trial of vitamin supplementation in senile dementia. Int J Ger Psychiat 4: 333–338CrossRefGoogle Scholar
  10. Burton G, Ingold K (1989) Vitamin E as an in vitro and vivo antioxidant. Ann NY Acad Sci 570: 7–21PubMedCrossRefGoogle Scholar
  11. Butterfield DA (1996) Commentary: Alzheimer’s disease: a disorder of oxidative stress. Alzheimer’s Dis Rev 1: 68–70Google Scholar
  12. Campi N, Todeschini GP, Scarzella L (1990) Selegiline versus 1-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 12: 306–314PubMedGoogle Scholar
  13. Dickson DW (1996) Commentary: Glycoxidation in Alzheimer’s disease: a specific mechanism of early lesion pathogenesis? Alzheimer’s Dis Rev 1: 75–76Google Scholar
  14. Falsaperla A, Monici Preti PA, Oliani C (1990) Selegiline versus oxiracetam in patients with Alzheimer’s type dementia. Clin Ther 12: 376–384PubMedGoogle Scholar
  15. Fahn S (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 32: 128–132CrossRefGoogle Scholar
  16. Finali G, Piccirilli M, Oliani C, Piccinin GL (1991) L-deprenyl therapy improves verbal memory in amnestic Alzheimer patients. Clin Neuropharmacol 14: 523–536PubMedCrossRefGoogle Scholar
  17. Finali G, Piccirilli M, Oliani C, Piccinin GL (1992) Alzheimer-type dementia and verbal memory performance: influence of selegiline therapy. Ital J Neurol Sci 13: 141–148PubMedCrossRefGoogle Scholar
  18. Fischer P, Götz ME, Danielczyk W, Gsell W, Riederer P (1997) Blood transferrin and ferritin in Alzheimer’s disease. Life Sci 60: 2273–2278PubMedCrossRefGoogle Scholar
  19. Frei B, England L, Ames B (1989) Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci 86: 6377–6381PubMedCrossRefGoogle Scholar
  20. Frölich L, Riederer P (1995) Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Drug Res 45: 443–446Google Scholar
  21. Gerlach M, Riederer P, Youdim MBH (1995) Neuroprotective therapeutic strategies. Biochem Pharmacol 50: 1–16PubMedCrossRefGoogle Scholar
  22. Gillis JC, Benfield P, Mctavish D (1994) Ide-benone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs and Aging 5: 133–152PubMedCrossRefGoogle Scholar
  23. Goad DL, Davis CM, Liem P, Fuselier CC, McCormack JR, Olsen KM (1991) The use of selegiline in Alzheimer’s patients with behavior problems. J Clin Psychiat 52: 342–345Google Scholar
  24. Götz ME, Fischer P, Gsell W, Riederer P, Streifler M, Simanyi M, Müller F, Danielczyk W (1998) Platelet monoamine oxidase B activity in dementia: a 4 year follow up. Dem Geriatr Cogn Disord 9: 74–77CrossRefGoogle Scholar
  25. Gsell W, Conrad R, Hickethier M, Sofic E, Frölich L, Wichart I, Jellinger K, Moll G, Ransmeyr G, Beckmann H, Riederer P (1995) Decreased catalase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64: 1216–1223PubMedCrossRefGoogle Scholar
  26. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59: 1609–1623PubMedCrossRefGoogle Scholar
  27. Hofferberth B (1994) The efficacy of Egb 761 in patients with senile dementia of the Alzheimer type, a double blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol 9: 215–222CrossRefGoogle Scholar
  28. Hoyer S (1997) Biochemie des alternden Hirnes. In: Rösler M, Retz W, Thome J (Hrsg) Die Alzheimer Krankheit. Beltz, Deutscher Studien Verlag, WeinheimGoogle Scholar
  29. Ihl R, Perisic I, Maurer K, Dierks T (1989) Effect of 3 months treatment with tenilsetam in patients suffering from dementia of Alzheimer type (DAT). J Neural Transm [PD-Sect] 1: 84–85CrossRefGoogle Scholar
  30. Jenner P (1994) Oxidative damage in neurodegenerative disease. Lancet 344: 796–798PubMedCrossRefGoogle Scholar
  31. Kanowski S, Herrmann WM, Staphan K, Wierich W, Hörr R (1996) Proof of efficacy of the Ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multiinfarct dementia. Pharmacopsychiatry 29: 47–56PubMedCrossRefGoogle Scholar
  32. Koutsilieri E, O’Callaghan JF, Chen TS, Riederer P, Rausch WD (1994) Selegiline enhances survival and neurite outgrowth of MPP+-treated dopaminergic neurons. Eur J Pharmacol 269: R3–R4PubMedCrossRefGoogle Scholar
  33. Lawlor B, Aisen P, Green C, Fine E, Schmeidler J (1997) Selegiline in the treatment of behavioural disturbance in Alzheimer’s disease. Int J Ger Psychiat 12: 319–322CrossRefGoogle Scholar
  34. Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, Marcone A, Smirne S (1991) Effects of a MAO-B inhibitor in the treatment of Alzheimer’s disease. Eur Neurol 31: 100–107PubMedCrossRefGoogle Scholar
  35. Martignoni E, Bono G, Blandini F, Sinforiani E, Merlo P, Nappi G (1991) Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer’s type. Influence of treatment with 1-deprenyl. J Neural Transm [PD-Sect] 3: 15–25CrossRefGoogle Scholar
  36. Mattson M (1997) Central role of oxyradicals in the mechanism of amyloid β-peptide cytotoxicity. Alzheimer’s Dis Rev 2: 1–14Google Scholar
  37. Meydani M (1995) Vitamin E. Lancet 345: 170–174PubMedCrossRefGoogle Scholar
  38. Monteverde A, Gnemmi P, Rossi F, Monteverde A (1990) Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 12: 315–322PubMedGoogle Scholar
  39. Münch G, Taneli Y, Schraven E, Schindler U, Schinzel R, Palm D, Riederer P (1994) The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylate. J Neural Transm [PD-Sect] 8: 193–208CrossRefGoogle Scholar
  40. Münch G, Simm A, Double KL, Riederer P (1996) Commentary: Oxidative stress and advanced glycation endproducts-parts of a vicious circle of neurodegeneration. Alzheimer’s Dis Rev 1: 71–74Google Scholar
  41. Nitta A, Murakami Y, Furukawa Y, Kawatsura W, Hayashi K, Yamada K, Hasegawa T, Nabeshima T (1994) Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basa forebrain-lesioned rats. Naunyn Schmiedebergs Arch Pharmacol 349: 410–407CrossRefGoogle Scholar
  42. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–183CrossRefGoogle Scholar
  43. Parnetti L (1995) Clinical pharmacokinetics of drugs for Alzheimer’s disease. Clin Pharmacokinet 29: 110–129PubMedCrossRefGoogle Scholar
  44. Parnetti L, Ambrosoli L, Abate G, Azzini C, Balestreri R, Bordin A, Crepaldi G, Christiani G, Cucinotta D (1995) Posatireline for the treatment of late onset Alzheimer’s disease: a double-blind multicentre study vs citicoline and ascorpic acid. Acta Neurol Scand 92: 135–140PubMedCrossRefGoogle Scholar
  45. Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, Bylsma F, Coyle JT, Mchugh PR, Folstein SE (1995) Trial of d-α-Tocopherol in Huntington’s disease. Am J Psychiatry 152: 1771–1775PubMedGoogle Scholar
  46. Piccinin GL, Final G, Piccirilli M (1990) Neuropsychological effects of 1-deprenyl in Alzheimer’s type dementia. Clin Neuropharmacol 13: 147–163PubMedCrossRefGoogle Scholar
  47. Rösler M, Retz W, Thome J, Riederer P (1998) Free radicals in Alzheimer’s dementia: currently available theraeutic strategies. J Neural Transm [Suppl] 53: 211–219Google Scholar
  48. Sano M, Ernesto C, Thomas R, Klauber M, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman C, Pfeifer E, Schneider L, Thal L (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336: 1216–1222PubMedCrossRefGoogle Scholar
  49. Schneider L, Pollo V, Zemansky M, Gleason R, Palmer R, Sloane B (1991) A pilot study of lowdose 1-deprenyl in Alzheimer’s disease. J Ger Psychiat Neurol 4: 143–148CrossRefGoogle Scholar
  50. Schneider L, Olin J, Pawluczyk S (1993) A double-blind crossover pilot study of 1-deprenyl (selegiline) combined with Cholinesterase inhibitor in Alzheimer’s disease. Am J Psychiatry 150: 321–323PubMedGoogle Scholar
  51. Senin U, Parnetti L, Barbagallo-Sangiorgi G, Bartorelli L, Bocola V, Capurso A, Cuzzupoli M, Denaro M, Margliano V, Tammaro AE, Fioravanti M (1992) Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr 15: 249–260PubMedCrossRefGoogle Scholar
  52. Smith MA, Sayre L, Perry G (1996) Is Alzheimer’s a disease of oxidative stress? Alzheimer’s Dis Rev 1: 63–67Google Scholar
  53. Stevens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson J, Brown MJ (1996) Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347: 781–787CrossRefGoogle Scholar
  54. Sunderland T, Tariot PN, Cohen RM, Newhouse PA, Mellow AM, Mueller EA, Murphy DL (1987) Dose-dependent effects of deprenyl on CSF metabolites in patients with Alzheimer’s disease. Psychopharmacology 91: 293–296PubMedCrossRefGoogle Scholar
  55. Suno M, Nagaoka A (1984) Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode oc action of the inhibition. Biochem Biophys Commun 125: 1046–1052CrossRefGoogle Scholar
  56. Tariot P, Cohen R, Sunderland T, Newhouse P, Yount D, Mellow A, Weingartner H, Mueller E, Murphy D (1987a) L-deprenyl in Alzheimer’s disease. Arch Gen Psychiatry 44: 427–433PubMedCrossRefGoogle Scholar
  57. Tariot P, Sunderland T, Weingartner H, Murphy D, Welkowitz J, Thompson K, Cohen R (1987b) Cognitive effects of 1-deprenyl in Alzheimer’s disease. Psychopharmacology 91: 489-95PubMedCrossRefGoogle Scholar
  58. Thome J, Münch G, Müller R, Schinzel R, Kornhuber J, Blum-Degen D, Sitzmann L, Rösler M, Heidland A, Riederer P (1996) Advanced glycation endproducts—associated parameters in the blood of patients with Alzheimer’s disease. Life Sci 59: 679–685PubMedCrossRefGoogle Scholar
  59. Thome J, Gsell W, Rösler M, Kornhuber J, Frölich L, Hashimoto E, Zielke B, Wiesbeck GA, Riederer P (1997) Oxidative-stress associated parameters (lactoferrin, superoxide dismutase) in serum of patients with Alzheimer’s disease. Life Sci 60: 13–19PubMedCrossRefGoogle Scholar
  60. Weitbrecht WU, Jansen W (1986) Primär degenerative Demenz: Therapie mit Ginkgo-biloba-Extract. Fortschr Med 104: 199–202PubMedGoogle Scholar
  61. Weyer G, Erzigkeit H, Hadler D, Kubicki S (1996) Efficacy and safety of idebenone in the longterm treatment of Alzheimer’s disease: a double-blind, placebo controlled multicentre study. Hum Psychopharmacol 11: 53–65CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • M. Rösler
  • W. Retz

There are no affiliations available

Personalised recommendations